<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002506</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000077957</org_study_id>
    <secondary_id>CBRG-9208</secondary_id>
    <secondary_id>NBSG-9208</secondary_id>
    <secondary_id>NCI-V92-0159</secondary_id>
    <nct_id>NCT00002506</nct_id>
  </id_info>
  <brief_title>Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer</brief_title>
  <official_title>ALPHA INTERFERON AND CIS-RETINOIC ACID FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMAS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoag Memorial Hospital Presbyterian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Biotherapy Research Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoag Memorial Hospital Presbyterian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. The use of isotretinoin may be an effective way to&#xD;
      prevent cancer or stop cancer from growing. Interferon alfa may interfere with the growth of&#xD;
      cancer cells. Combining isotretinoin and interferon may be an effective treatment for some&#xD;
      recurrent cancers.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of interferon alfa plus isotretinoin in&#xD;
      treating patients with recurrent cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rates to treatment with daily subcutaneous interferon&#xD;
      alpha plus oral isotretinoin in patients with advanced squamous cell carcinomas of the&#xD;
      following body sites: head and neck, cervix, skin, esophagus, lung, and penis. II. Determine&#xD;
      the toxicities and side effects of this treatment.&#xD;
&#xD;
      OUTLINE: Nonrandomized study. Single-agent Chemotherapy with Biological Response Modifier&#xD;
      Therapy. Isotretinoin, 13-CRA, NSC-329481; with Interferon alpha (Schering or Hoffmann-La&#xD;
      Roche), IFN-A, NSC-377523 or NSC-367982.&#xD;
&#xD;
      PROJECTED ACCRUAL: 14-50 patients per tumor category (and any other tumor location, if&#xD;
      available) will be enrolled. If none of the first 14 patients in any tumor category responds,&#xD;
      or if only 1/22, 2/30, 3/37, 4/44, or 5/50 respond, the treatment will be considered&#xD;
      ineffective for that tumor type.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1992</start_date>
  <completion_date type="Actual">February 1999</completion_date>
  <primary_completion_date type="Actual">January 1996</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Non-melanomatous Skin Cancer</condition>
  <condition>Penile Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven squamous cell carcinoma that has failed&#xD;
        standard local modalities for local disease and/or effective systemic therapy for&#xD;
        metastatic disease, or for which other forms of systemic therapy have been refused Eligible&#xD;
        sites include but are not limited to: Uterine cervix Head and neck Skin Esophagus Lung&#xD;
        Penis Measurable or evaluable disease required Measurable disease defined as previously&#xD;
        unirradiated disease reproducibly measurable in 2 dimensions by physical exam, x-ray, CT,&#xD;
        MRI, or other radiologic procedure Documented progressive disease in a previously&#xD;
        irradiated site is accepted as measurable Evaluable disease includes: Any visible&#xD;
        radiologic disease not measurable in 2 perpendicular diameters Elevated squamous cell&#xD;
        carcinoma antigen (SCCA) No active brain metastases Previously treated brain metastases&#xD;
        that have responded to therapy do not exclude, but CNS disease is not considered measurable&#xD;
        or evaluable&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Hematopoietic: WBC&#xD;
        at least 3,000 Platelets at least 100,000 Hct at least 30% Hepatic: Bilirubin less than 2.0&#xD;
        mg/dl PT normal PTT normal Renal: Creatinine less than 2.0 mg/dl Cardiovascular: No MI&#xD;
        within 6 months No CHF requiring medication No arrhythmia requiring medication Pulmonary:&#xD;
        Reasonable respiratory reserve required No requirement for supplemental oxygen No dyspnea&#xD;
        at rest Other: No chronic underlying immunodeficiency disease No HIV positivity No pregnant&#xD;
        patients (negative pregnancy test required) Adequate birth control required of fertile&#xD;
        patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No concomitant immunosuppressive drugs, e.g.,&#xD;
        cyclosporin Chemotherapy: At least 3 weeks since prior systemic chemotherapy with recovery&#xD;
        Endocrine therapy: No concomitant corticosteroids Radiotherapy: No prior radiotherapy to&#xD;
        measurable site unless disease progression is documented Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert O. Dillman, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Biotherapy Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bloomington Hospital</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Regional Cancer Center - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Regional Cancer Center</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dillman RO, Soori G, Tai DF, et al.: Interferon alpha-2A (FN) and cis-retinoic acid (CRA) for the treatment of squamous cell carcinoma (SCC): a preliminary report. J Immunother 20(5): 404, 1997.</citation>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2004</study_first_posted>
  <last_update_submitted>May 10, 2011</last_update_submitted>
  <last_update_submitted_qc>May 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Robert O. Dillman, MD</name_title>
    <organization>Hoag Memorial Hospital Presbyterian</organization>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>squamous cell carcinoma of the skin</keyword>
  <keyword>recurrent penile cancer</keyword>
  <keyword>recurrent skin cancer</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>penile squamous cell carcinoma</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

